An intravenous recombinant enzyme for the treatment of toxic levels of methotrexate due to kidney failure.
Marketed as Voraxaze.
Prolonged exposure to high levels of methotrexate can lead to renal failure, liver damage, stomatitis, enteritis, skin rashes, and myelosuppression.
Results in 95% reduction in methotrexate concentration from pretreatment baseline levels and is maintained for up to 8 days.
Most common side effects are hypotension, headache, nausea, vomiting, flushing and paresthesias.